You are here: Industry Insights > Dapagliflozin

News List

NICE recommend dapagliflozin for treating chronic kidney disease EuropeanPharmaceuticalReview
November 09, 2021
The National Institute for Health and Care Excellence (NICE) has recommended dapagliflozin as an option for treating certain individuals with chronic kidney disease (CKD) in new draft guidance.
NICE recommends AstraZeneca’s dapagliflozin to treat chronic kidney disease Pharmaceutical-Business-Review
November 09, 2021
The UK’s National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s dapagliflozin as a treatment for people with chronic kidney disease (CKD).
No Increase in Risk With Dapagliflozin in Patients With Stage 4 CKD drugs
July 22, 2021
For patients with stage 4 chronic kidney disease (CKD), a similar pattern of reduced kidney, cardiovascular, and mortality risks is seen with dapagliflozin versus placebo, with no evidence of increased risks.
Da-pag-li-flo-zin is Well Tolerated in Hospitalized Patients firstwordpharma
June 28, 2021
DARE-19 is the first large randomized clinical trial to assess sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with and without type 2 diabetes hospitalized with COVID-19.
Mankind Pharma launches Justoza, a Dapagliflozin approved by USFDA expresspharma
June 23, 2021
The Active Pharmaceutical Ingredient (API) is procured from the Drug Master File (DMF) facility approved by USFDA, EU GMP and WHO GMP, which ensures the highest global efficacy and safety standards.
Astrazeneca gives rights to trademark for three diabetes drug brands to Sun Pharma expresspharma
May 31, 2021
Consequently, AstraZeneca India and Sun Pharma have discontinued their existing distribution services agreement signed in 2016, for the distribution of Dapagliflozin.
Micro Labs launches anti-diabetic drug combo, Dapagliflozin plus Metformin expresspharma
November 25, 2020
The drug comes in two strengths ZUCAPRIDE–M 500 priced at Rs12.80 per tablet and ZUCAPRIDE–M 1000 at Rs 14.80.
Zydus Cadila gets tentative US FDA approval for Dapagliflozin Tablets expresspharma
October 30, 2020
Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated to improve glycemic control in adults with type 2 diabetes mellitus.
Diabetes drug, Dapagliflozin shows benefits in patients with CKD expresspharma
September 01, 2020
The drug, on top of standard of care, reduced the composite measure of worsening of renal function or risk of cardiovascular (CV) or renal death by 39 per cent.
Astrazeneca’s Dapagliflozin gets DCGI nod for treatment of heart failure expresspharma
July 06, 2020
Dapagliflozin (Forxiga) is an SGLT-2 inhibitor that can reduce the risk of cardiovascular death and hospitalisation for heart failure in patients with HFrEF.

Previous page 1 2 Next page